Exogenus Therapeutics CEO, Joana Simões Correia, is a Finalist of the European Lifestars Awards 2026

Cantanhede, Portugal, 15 September 2026 – Exogenus Therapeutics, is proud to announce that its Chief Executive Officer, Joana Simões Correia, has been selected as a finalist in the Women-Led Business of the Year category at the European Lifestars Awards 2026.

Organised by Informa Connect, the organisation behind BIO-Europe, one of the world’s leading partnering events for the biotechnology and biopharmaceutical industries, the European Lifestars Awards celebrate exceptional leadership, innovation and value creation across the European life sciences ecosystem.

The nomination recognises Joana Simões Correia’s leadership in advancing Exogenus Therapeutics’ mission to develop next-generation regenerative medicine solutions and in positioning the company as an emerging innovator within the European biotechnology landscape.

Founded to unlock the therapeutic potential of exosome-based technologies, Exogenus Therapeutics has been working to advance innovative approaches in regenerative medicine, with the ambition of addressing significant unmet medical needs through cutting-edge science and translational innovation.

“I am deeply honoured to be recognised among such an inspiring group of leaders from across Europe. Being named a finalist in the Women-Led Business of the Year category is particularly meaningful, at a time when women continue to be underrepresented in senior leadership positions across the life sciences industry and the wider business world. This nomination is ultimately a reflection of the talent, resilience and dedication of the entire Exogenus team, as well as the support of our collaborators, investors and partners who share our vision for the future of regenerative medicine,” said Joana Simões Correia, CEO of Exogenus Therapeutics.

The European Lifestars Awards bring together senior executives, investors, business development leaders and industry stakeholders from across Europe to recognise the individuals and organisations driving scientific progress, strategic growth and meaningful impact throughout the life sciences sector.

For Exogenus Therapeutics, this recognition represents an important milestone in the company’s continued international development and highlights the growing relevance of Portuguese biotechnology on the global stage.

The winners of the European Lifestars Awards will be announced during the awards ceremony held in London on 16 November 2026, and a complete list pf the finalists can be found here (https://informaconnect.com/european-lifestars-awards/finalists/) .